Combinational Treatment of Imatinib and Allicin Synergistically Inhibits the Growth of BCR-ABL-Positive Leukemia and the Emergence of Drug-Resistant Cells

被引：0
|
作者：
Lim, Jamie
Kim, Jung-Hyun
Ahn, Eun-Young Erin
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4992
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors
    Radujkovic, Aleksandar
    Topaly, Julian
    Fruehauf, Stefan
    Zeller, W. Jens
    ANTICANCER RESEARCH, 2006, 26 (3A) : 2169 - 2177
  • [2] Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies
    Ellen Weisberg
    Atsushi Nonami
    James D. Griffin
    Archives of Toxicology, 2014, 88 : 2233 - 2242
  • [3] Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies
    Weisberg, Ellen
    Nonami, Atsushi
    Griffin, James D.
    ARCHIVES OF TOXICOLOGY, 2014, 88 (12) : 2233 - 2242
  • [4] NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice
    Chen, Ci-U
    Koschmieder, S.
    Kerstiens, L.
    Schemionek, M.
    Altvater, B.
    Pscherer, S.
    Gerss, J.
    Maecker, H. T.
    Berdel, W. E.
    Juergens, H.
    Lee, P. P.
    Rossig, C.
    LEUKEMIA, 2012, 26 (03) : 465 - 474
  • [5] Successful Treatment with Imatinib Mesylate in a Case of Minor BCR-ABL-Positive Acute Myelogenous Leukemia
    Katsuro Ito
    Kazunori Tominaga
    Toshiya Suzuki
    Itsuro Jinnai
    Masami Bessho
    International Journal of Hematology, 2005, 81 : 242 - 245
  • [6] Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells
    Kominsky, Douglas J.
    Klawitter, Jelena
    Brown, Jaimi L.
    Boros, Laszlo G.
    Melo, Junia V.
    Eckhardt, S. Gail
    Serkova, Natalie J.
    CLINICAL CANCER RESEARCH, 2009, 15 (10) : 3442 - 3450
  • [7] Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia
    Ito, K
    Tominaga, K
    Suzuki, T
    Jinnai, I
    Bessho, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (03) : 242 - 245
  • [8] The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
    Haass, Wiltrud
    Stehle, Michael
    Nittka, Stefanie
    Giehl, Michelle
    Schrotz-King, Petra
    Fabarius, Alice
    Hofmann, Wolf-Karsten
    Seifarth, Wolfgang
    PLOS ONE, 2012, 7 (08):
  • [9] Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
    J Dengler
    N von Bubnoff
    T Decker
    C Peschel
    J Duyster
    Leukemia, 2005, 19 : 1835 - 1838
  • [10] Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
    Dengler, J
    von Bubnoff, N
    Decker, T
    Peschel, C
    Duyster, J
    LEUKEMIA, 2005, 19 (10) : 1835 - 1838
12345